Q-omics provides the consensus-scored TMEM30BP1 profile across patient tissues and cancer cell-line models. TMEM30BP1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TMEM30BP1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TMEM30BP1 RNA expression shows 17,939 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, KIRC, and THYM as cancer lineages where TMEM30BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM30BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM30BP1 survival associations across molecular data types. TMEM30BP1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM30BP1 RNA expression–survival associations across cancer types. High TMEM30BP1 expression shows unfavorable associations in KICH, LGG, KIRC, KIRP, THCA and ACC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KICH as the clearest survival context for TMEM30BP1 RNA expression.
This table summarizes TMEM30BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM30BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM30BP1 shows higher tumor expression in KIRC, HNSC, STAD, BLCA, CHOL and COAD. The KIRC box plot shows higher TMEM30BP1 RNA expression in tumor versus normal tissue (log2 FC = +0.357, t-test p < 0.001).
This table shows molecular features associated with TMEM30BP1 in patient tissues and cancer cell lines. In patient samples, TMEM30BP1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
